Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment
Abstract
approximately 5-7% of people in Russia have diabetes. In addition, the number is growing every year. Diabetes treatment schemes mostly focused on normalizing the blood glucose level. To achieve it patients use the glucose meters. However, there are some technique differences between meters that could influence on the cost and effectiveness of diabetes and its complications treatment. This pharmacoeconomic research compared the cost-effectiveness and the budget impact results of using Contour TS, Accu-Chek Active and OneTouch Select. Research outcomes demonstrate the pharmacoeconomic advantages of using Contour TS as blood glucose meter in diabetes treatment schemes.
About the Authors
A. U. KulikovRussian Federation
MD, PhD, Key scientific specialist of the Laboratory of pharmacoeconomic researches, Head of the pharmacoeconomics course of department of organization of medicinal provision and pharmacoeconomic
First Moscow State Medical University named I.M. Sechenov. Moscow, Russia tel: +7 (926) 800-10-56
V. V. Babiy
Russian Federation
References
1. Серпик В.Г. Теоретические основы биостатистики при проведении фармакоэкономических исследований. Фармакоэкономика. 2009; 2: 9-14.
2. Ягудина Р.И., Куликов А.Ю., Комаров И.А. Методология проведения анализа «затрат» при проведении фармакоэкономических исследований. Фармакоэкономика. 2011; 3: 3-6.
3. Ягудина Р. И., Куликов А.Ю., Новиков И.В. Современная методология анализа чувствительности в фармакоэкономических исследованиях. Фармакоэкономика. 2010; 4: 8-12.
4. Ягудина Р.И., Куликов А.Ю. Теоретические основы фармакоэкономического метода: анализ «влияния на бюджет». Фармакоэкономика. 2011; 2: 9-12.
5. Central Statistical Office of Poland. National Census of People and Dwellings 2011. [home page on the Internet]: htpps://www.stat. gov.pl.
6. Charles H. Raine, Linda E., Schrock, R.N., Steven V. Edelman, Sunder Raj D. Mudaliar, Weiping Zhong, Lois J. Proud, Joan Lee Parkes. Significant insulin dose errors may occur if blood glucose results are obtained from miscoded meters. Journal of Diabetes Science and Technology. 2007; 1 (2).
7. Farmer A., Wade A., Goyder E. et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomized trial. BMJ. 2007; 335 (7611): 132.
8. Holko P., Kawalec P. Cost effectiveness and cost utility of the non-coding blood glucose meter Contour TS. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2011; 4:79-88.
9. https://www.rosminzdrav.ru.
10. https://www.pharmindex.ru.
11. https://www.mma.ru.
12. Martin S., Schneider B., Heinemann L., Lodwig V., Kurth H.J., Kolb H., Scherbaum W.A. Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study (ROSSO). Diabetologia . 2006.
13. Sonnenberg F.A., Beck J.R. Markov models in medical decision making: a practical guide. Med. Decis. Making. 1993; 13: 322-338.
14. Stratton I.M., Adler A.I., Neil HAW. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321 (7258): 405-412.
Review
For citations:
Kulikov A.U., Babiy V.V. Pharmacoeconomic analysis of blood glucose meter Contour TS in diabetes treatment. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2013;6(4):53-58.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 